Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma Save

Date Added
December 20th, 2016
PRO Number
Pro00061291
Researcher
Juan Varela
Keywords
Cancer/Myeloma
Summary

This study is for adult patients who have high risk myeloma (MM), a cancer of the plasma cells that begins in their bone marro OR their MM returned after an autologous transplant. The study is being done to learn if maintenance treatment (chemotherapy) works better to control your disease than placebo.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login